141 related articles for article (PubMed ID: 36472651)
1. Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis.
Sayyid RK; Benton JZ; Reed WC; Woodruff P; Terris MK; Wallis CJD; Klaassen Z
World J Urol; 2023 Jan; 41(1):93-99. PubMed ID: 36472651
[TBL] [Abstract][Full Text] [Related]
2. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
3. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis.
Chandrasekar T; Bowler N; Schneider A; Goldberg H; Mark JR; Trabulsi EJ; Lallas CD; Gomella LG
Urology; 2021 Sep; 155():101-109. PubMed ID: 34186134
[TBL] [Abstract][Full Text] [Related]
5. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
[TBL] [Abstract][Full Text] [Related]
6. Influence of Active Surveillance on Gleason Score Upgrade and Prognosis in Low- and Favorable Intermediate-Risk Prostate Cancer.
Hu X; Miao J; Huang J; Qian L; Zhang D; Wei H
Curr Oncol; 2022 Oct; 29(10):7964-7978. PubMed ID: 36290907
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
8. Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decision.
Sayyid RK; Reed WC; Benton JZ; Lodh A; Woodruff P; Lambert JH; Terris MK; Wallis CJD; Klaassen Z
Urol Oncol; 2021 Nov; 39(11):782.e7-782.e14. PubMed ID: 33766466
[TBL] [Abstract][Full Text] [Related]
9. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
[TBL] [Abstract][Full Text] [Related]
10. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
11. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance.
Sherer MV; Leonard AJ; Nelson TJ; Courtney PT; Guram K; Rodrigues De Moraes G; Javier-Desloges J; Kane C; McKay RR; Rose BS; Bagrodia A
Eur Urol Open Sci; 2023 Apr; 50():61-67. PubMed ID: 37101776
[TBL] [Abstract][Full Text] [Related]
13. Cause-specific mortality of low and selective intermediate-risk prostate cancer patients with active surveillance or watchful waiting.
Wu X; Lv D; Eftekhar M; Cai C; Zhao Z; Gu D; Liu Y
Transl Androl Urol; 2021 Jan; 10(1):154-163. PubMed ID: 33532305
[TBL] [Abstract][Full Text] [Related]
14. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
15. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
16. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice.
Sayyid RK; Klotz L; Benton JZ; Ma M; Woodruff P; Satkunasivam R; Terris MK; Wallis CJD; Klaassen Z
Can Urol Assoc J; 2022 Jan; 16(1):E7-E14. PubMed ID: 34464250
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience.
Bandelier Q; Bastide C; Charvet AL; Leclercq L; Gondran-Tellier B; Campagna J; Long-Depaquit T; Daniel L; Rossi D; Lechevallier E; Baboudjian M
Fr J Urol; 2024 Jan; 34(1):102537. PubMed ID: 37783635
[TBL] [Abstract][Full Text] [Related]
19. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
[TBL] [Abstract][Full Text] [Related]
20. Association of extended core sampling with delayed intervention and pathologic outcomes for active surveillance patients A population-based analysis.
Sayyid RK; Bernardino R; Al-Daqqaq Z; Tiwari R; Al-Rumayyan M; Sildva T; Cockburn JG; Klaassen Z; Fleshner NE
Can Urol Assoc J; 2024 May; 18(5):E142-E151. PubMed ID: 38319602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
